EAGAN, Minn., May 6, 2021 /PRNewswire/ Â Prime Therapeutics LLC s (Prime) President and CEO Ken Paulus is joining over 2,000 other chief executive officers by signing the CEO Action for Diversity & Inclusion pledge. It is the largest CEO-driven business commitment to advance diversity and inclusion (D&I) in the workplace. By signing the CEO Action for Diversity & Inclusion pledge, we are committing to promote D&I efforts at work and in the community, said Paulus. Fostering a diverse and inclusive workplace creates greater innovation and collaboration, which makes us a stronger company and empowers us to better serve our clients and members.
The CEO Action for Diversity & Inclusion commitment is driven by a realization that addressing D&I is a societal issue, not a competitive issue. The pledge acknowledges that executives play a key role in positive change. Companies from 85 different industries have taken part in the pledge, and signees are given unique perspective on devel
Prime Therapeutics Ups Its Predictive Analytics Game with Differentiated Integrated Data Platform mesabitribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mesabitribune.com Daily Mail and Mail on Sunday newspapers.
EAGAN, Minn., April 12, 2021 /PRNewswire/ Blue Cross and Blue Shield plans can better forecast and manage the total cost of chimeric antigen receptor T-cell (CAR-T) therapies for members
Share this article
Share this article
EAGAN, Minn., April 7, 2021 /PRNewswire/ Armed with insights from substantive, real-world data, Blue Cross and Blue Shield plans that partner with Prime Therapeutics LLC (Prime) are now more effectively making data-driven decisions to mitigate the high costs of autoimmune therapies for inflammatory conditions and multiple sclerosis (MS). Recently, Prime analyzed integrated pharmacy and medical claims data for specialty drug use in autoimmune conditions – the top cost drivers among all drug health care expenses. At 22% of all drug expenditures through the medical and pharmacy benefits among Prime s commercially insured book of business, autoimmune therapy costs for inflammatory conditions and MS account for $6.7 billion annually.